Tempus AI expands oncology data partnership with Bristol Myers Squibb through 2031
BMY•Tempus AI expanded its oncology data licensing agreement with Bristol Myers Squibb through 2031. Bristol Myers Squibb will access de-identified oncology data and Tempus AI’s Lens Platform, including dedicated GPU infrastructure, to train and run AI models.
1. Expanded data agreement
Tempus AI expanded its multiyear oncology data licensing agreement with Bristol Myers Squibb, which runs through 2031. The agreement makes Bristol Myers Squibb one of Tempus AI’s largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development.
2. Access to AI platform
Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure.
